Skip to main content
. 2018 Nov 26;18:1171. doi: 10.1186/s12885-018-5078-y

Fig. 3.

Fig. 3

a, b Waterfall plots of the best percentage change of crizotinib in target lesions at baseline in ALK-positive patients with (b) or without c-Met overexpression (a). c PFS of crizotinib in ALK-positive patients with or without c-Met overexpression; d OS of ALK-positive patients with or without c-Met overexpression